Current chemotherapy options for thymic epithelial neoplasms

Kyriakos P. Papadopoulos, Charles Thomas

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Thymomas and thymic carcinoma are rare neoplasms. Surgical resection is the cornerstone of effective therapy. Stage I disease is effectively treated by complete surgical resection. The role of radiation therapy in completely resected stage II disease remains controversial. Adjuvant radiation therapy is useful for local control and may improve survival in patients with incompletely resected tumours. Cisplatin-based chemotherapy regimens play an important role in the treatment of advanced stage III/IV or recurrent disease thymomas, but have proven less effective for thymic carcinoma. Phase II trials of multimodality therapy incorporating neoadjuvant chemotherapy, surgery and postoperative radiation therapy show promise for unresectable disease. This review discusses recent clinical data and the potential role for agents targeting the epidermal growth factor receptor, angiogenesis and apoptotic pathways.

Original languageEnglish (US)
Pages (from-to)1169-1177
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Volume6
Issue number7
DOIs
StatePublished - Jun 2005
Externally publishedYes

Fingerprint

Thymus Neoplasms
Thymoma
Glandular and Epithelial Neoplasms
Drug Therapy
Radiotherapy
Neoadjuvant Therapy
Epidermal Growth Factor Receptor
Cisplatin
Neoplasms
Survival
Therapeutics

Keywords

  • Chemotherapy
  • Targeted therapy
  • Thymic carcinoma
  • Thymoma

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Current chemotherapy options for thymic epithelial neoplasms. / Papadopoulos, Kyriakos P.; Thomas, Charles.

In: Expert Opinion on Pharmacotherapy, Vol. 6, No. 7, 06.2005, p. 1169-1177.

Research output: Contribution to journalArticle

@article{f284d1dae60c4076b7da546137766fcf,
title = "Current chemotherapy options for thymic epithelial neoplasms",
abstract = "Thymomas and thymic carcinoma are rare neoplasms. Surgical resection is the cornerstone of effective therapy. Stage I disease is effectively treated by complete surgical resection. The role of radiation therapy in completely resected stage II disease remains controversial. Adjuvant radiation therapy is useful for local control and may improve survival in patients with incompletely resected tumours. Cisplatin-based chemotherapy regimens play an important role in the treatment of advanced stage III/IV or recurrent disease thymomas, but have proven less effective for thymic carcinoma. Phase II trials of multimodality therapy incorporating neoadjuvant chemotherapy, surgery and postoperative radiation therapy show promise for unresectable disease. This review discusses recent clinical data and the potential role for agents targeting the epidermal growth factor receptor, angiogenesis and apoptotic pathways.",
keywords = "Chemotherapy, Targeted therapy, Thymic carcinoma, Thymoma",
author = "Papadopoulos, {Kyriakos P.} and Charles Thomas",
year = "2005",
month = "6",
doi = "10.1517/14656566.6.7.1169",
language = "English (US)",
volume = "6",
pages = "1169--1177",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Current chemotherapy options for thymic epithelial neoplasms

AU - Papadopoulos, Kyriakos P.

AU - Thomas, Charles

PY - 2005/6

Y1 - 2005/6

N2 - Thymomas and thymic carcinoma are rare neoplasms. Surgical resection is the cornerstone of effective therapy. Stage I disease is effectively treated by complete surgical resection. The role of radiation therapy in completely resected stage II disease remains controversial. Adjuvant radiation therapy is useful for local control and may improve survival in patients with incompletely resected tumours. Cisplatin-based chemotherapy regimens play an important role in the treatment of advanced stage III/IV or recurrent disease thymomas, but have proven less effective for thymic carcinoma. Phase II trials of multimodality therapy incorporating neoadjuvant chemotherapy, surgery and postoperative radiation therapy show promise for unresectable disease. This review discusses recent clinical data and the potential role for agents targeting the epidermal growth factor receptor, angiogenesis and apoptotic pathways.

AB - Thymomas and thymic carcinoma are rare neoplasms. Surgical resection is the cornerstone of effective therapy. Stage I disease is effectively treated by complete surgical resection. The role of radiation therapy in completely resected stage II disease remains controversial. Adjuvant radiation therapy is useful for local control and may improve survival in patients with incompletely resected tumours. Cisplatin-based chemotherapy regimens play an important role in the treatment of advanced stage III/IV or recurrent disease thymomas, but have proven less effective for thymic carcinoma. Phase II trials of multimodality therapy incorporating neoadjuvant chemotherapy, surgery and postoperative radiation therapy show promise for unresectable disease. This review discusses recent clinical data and the potential role for agents targeting the epidermal growth factor receptor, angiogenesis and apoptotic pathways.

KW - Chemotherapy

KW - Targeted therapy

KW - Thymic carcinoma

KW - Thymoma

UR - http://www.scopus.com/inward/record.url?scp=21844472786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21844472786&partnerID=8YFLogxK

U2 - 10.1517/14656566.6.7.1169

DO - 10.1517/14656566.6.7.1169

M3 - Article

C2 - 15957970

AN - SCOPUS:21844472786

VL - 6

SP - 1169

EP - 1177

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 7

ER -